BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2814920)

  • 1. [Acute monoblastic leukemia in non-Hodgkin's malignant lymphoma treated with prednimustine].
    Mahe M; Raffi F; Grolleau JY; Baudot S
    Therapie; 1989; 44(5):378-9. PubMed ID: 2814920
    [No Abstract]   [Full Text] [Related]  

  • 2. Prednimustine treatment in malignant lymphomas.
    Szántó I; Fleischmann T; Eckhardt S
    Oncology; 1989; 46(4):205-7. PubMed ID: 2662086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of Prednimustine. Leo-1031 (NSC-134087) in acute non-lymphocytic leukemia.
    Juul K; Sørensen P; Pedersen-Bjergaard J; Jensen MK
    Scand J Haematol; 1979 Nov; 23(5):388-92. PubMed ID: 396664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic lymphocytic leukaemia and well-differentiated lymphocytic lymphoma with continuous low- or intermittent high-dose prednimustine versus chlorambucil/prednisolone.
    Ideström K; Kimby E; Björkholm M; Mellstedt H; Engstedt L; Gahrton G; Johansson B; Killander D; Robérts KH; Stalfelt AM; Udén AM; Wadman B; Wählby S
    Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1117-23. PubMed ID: 6897633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients.
    Tirelli U; Zagonel V; Sorio R; Errante D; Talamini R; Carbone A; Monfardini S
    Semin Hematol; 1994 Apr; 31(2 Suppl 3):13-22. PubMed ID: 8073302
    [No Abstract]   [Full Text] [Related]  

  • 6. Prednimustine in refractory non-Hodgkin's lymphoma: a phase II study of the Northern California Oncology Group.
    Gandara DR; Wold HG; Redmond J; Kohler M; Reynolds R; Wong P; Forsythe J; Fisher K; Lewis B
    Semin Oncol; 1986 Mar; 13(1 Suppl 1):14-8. PubMed ID: 3952517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only--a preliminary update of the German Low-Grade Lymphoma Study Group.
    Hiddemann W; Unterhalt M; Koch P; Nahler M; Herrmann R
    Semin Hematol; 1994 Apr; 31(2 Suppl 3):32-5. PubMed ID: 8073307
    [No Abstract]   [Full Text] [Related]  

  • 8. A phase II clinical trial of prednimustine. Clinical screening cooperative group of E.O.R.T.C.
    Biomedicine; 1977 Jun; 27(4):158-61. PubMed ID: 329910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial of prednimustine, Leo-1031 (NSC-134087), in patients with non-Hodgkin lymphomata and chronic lymphocytic leukaemia previously treated with steroids and alkylating agents.
    Pedersen-Bjergaard J; Hansen MM; Geisler CH; Nissen NI
    Acta Med Scand; 1980; 207(3):215-20. PubMed ID: 6989170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prednimustine in advanced malignant melanoma: a phase II study.
    Pedersen L; Løber J; Dalmark M; Mouridsen HT
    Cancer Treat Rep; 1987 Dec; 71(12):1315-6. PubMed ID: 3690549
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts.
    Gandara DR; Ries CA; Schiff SA; George CB; Lewis JP; Koretz MM; Carter SK
    Cancer Chemother Pharmacol; 1982; 9(1):10-2. PubMed ID: 7139848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of prednimustine in glioblastoma multiforme.
    Andersen J; Christensen L; Kongsholm H
    Cancer Treat Rep; 1984 May; 68(5):795-7. PubMed ID: 6327038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prednimustine in adult acute myeloid leukaemia.
    Brandt L; Könyves I
    Cancer Chemother Pharmacol; 1979; 2(2):133-6. PubMed ID: 394873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prednimustine: the rationale for clinical development.
    Schein PS; Cavalli F
    Semin Oncol; 1986 Mar; 13(1 Suppl 1):1-2. PubMed ID: 3952515
    [No Abstract]   [Full Text] [Related]  

  • 15. Continuous versus intermittent prednimustine treatment of non-Hodgkin's lymphoma.
    Hatschek T; Baldetorp L; Carstensen J; Håkansson L; Möller T; Nilsson B; Termander B
    Med Oncol Tumor Pharmacother; 1993; 10(4):159-66. PubMed ID: 8164452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase III study of prednimustine (LEO 1031) in advanced breast cancer. A preliminary report.
    Rørth M; Løber J; Dombernowsky P; Krusenstjerna-Hofstrom D; Mattsson W; Mouridsen HT
    Eur J Cancer (1965); 1980; Suppl 1():137-40. PubMed ID: 7032923
    [No Abstract]   [Full Text] [Related]  

  • 17. Prednimustine in combination with methotrexate and 5-FU (PMF): a pilot study.
    Boesen E; Mouridsen HT
    Cancer Treat Rep; 1982 Dec; 66(12):2081-3. PubMed ID: 7139649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pharmacokinetics of chlorambucil and prednimustine after oral administration.
    Loos U; Musch E; Malek M; Riedel E
    Oncology; 1991; 48(4):334-42. PubMed ID: 1891177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prednimustine in elderly patients with multiple myeloma: a phase II study.
    Tirelli U; Sorio R; Magri MD; Zagonel V; Vaccher E; Carbone A; Trovò M; Grigoletto E
    Cancer Treat Rep; 1986 Apr; 70(4):537-8. PubMed ID: 3698051
    [No Abstract]   [Full Text] [Related]  

  • 20. Prednimustine for prostate cancer therapy.
    Slack NH; Murphy GP
    Compr Ther; 1979 Sep; 5(9):54-7. PubMed ID: 487742
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.